1 (currently amended). A compound of the formula I

wherein

R1, R2 are each independently H, F, Cl, Br, (C_1-C_6) -alkyl, CF_3 , OCF_3 , NO_2 , CN, O- (C_1-C_6) -alkyl, $COO(C_1-C_6)$ -alkyl, $COO(C_1-C_6)$ -alkyl, $COO(C_1-C_6)$ -alkyl or $SO_2-(C_1-C_6)$ -alkyl;

is OH, (C₁-C₆)-alkyl, (C₀-C₆)-alkyl-aryl, O-(C₁-C₆)-alkyl, O-(C₂-C₆)-alkenyl or O-(C₂-C₆)-alkynyl, wherein said (C₁-C₆)-alkyl, (C₀-C₆)-alkyl-aryl, O-(C₁-C₆)-alkyl, O-(C₂-C₆)-alkenyl and O-(C₂-C₆)-alkynyl radicals are optionally mono- or polysubstituted by F, Cl or Br;

X is OH, O- (C_1-C_6) -alkyl, NH₂, NH (C_1-C_6) -alkyl or N((C_1-C_6) -alkyl)₂;

A, B, D and E are each independently CH or N, with the provise that at least one of groups A, B, D and E is N;

B, D and E are CH;

m is [[0, 1 or]] 2;

[[and]] or a pharmaceutically acceptable salt[[s]] thereof.

2 (currently amended). The compound of Claim 1 wherein:

R1, R2 are each independently H, F, Cl, Br, (C_1-C_6) -alkyl, CF_3 , OCF_3 , NO_2 , CN, O- (C_1-C_6) -alkyl, $COO(C_1-C_6)$ -alkyl, $COO(C_1-C_6)$ -alkyl, $COO(C_1-C_6)$ -alkyl or $SO_2-(C_1-C_6)$ -alkyl;

is OH, (C₁-C₆)-alkyl, (C₀-C₆)-alkyl-aryl, O-(C₁-C₆)-alkyl, O-(C₂-C₆)-alkenyl or O-(C₂-C₆)-alkynyl, wherein said (C₁-C₆)-alkyl, (C₀-C₆)-alkyl-aryl, O-(C₁-C₆)-alkyl, O-(C₂-C₆)-alkenyl and O-(C₂-C₆)-alkynyl radicals are optionally mono- or polysubstituted by F, Cl or Br;

X is OH, O-(C_1 - C_6)-alkyl, NH₂, NH(C_1 - C_6)-alkyl or N((C_1 - C_6)-alkyl)₂;

A, B, D and E are each independently CH or N, with the provise that at least one of groups A, B, D and E is N;

B, D and E are CH;

m is [[1 or]] 2;

[[and]] or a pharmaceutically acceptable salt[[s]] thereof.

3 (currently amended). The compound of Claim 2 wherein:

R1 is H or F;

R2 is each independently H, F, Cl, Br, (C_1-C_6) -alkyl, CF_3 , OCF_3 , $O-(C_1-C_6)$ -alkyl, $COO(C_1-C_6)$ -alkyl,

is OH, (C₁-C₆)-alkyl, (C₀-C₆)-alkyl-aryl, O-(C₁-C₆)-alkyl, O-(C₂-C₆)-alkenyl or O-(C₂-C₆)-alkynyl, wherein said (C₁-C₆)-alkyl, (C₀-C₆)-alkyl-aryl, O-(C₁-C₆)-alkyl, O-(C₂-C₆)-alkenyl and O-(C₂-C₆)-alkynyl radicals are optionally mono- or polysubstituted by F, Cl or Br;

X is OH, O- (C_1-C_6) -alkyl, NH₂, NH (C_1-C_6) -alkyl or N((C_1-C_6) -alkyl)₂;

A is N;

B, D, E are each CH;

m is [[1 or]] 2;

[[and]] or a pharmaceutically acceptable salt[[s]] thereof.

4 (currently amended). The compound of Claim 3 wherein:

R1 is H or F;

R2 is H, Cl, (C₁-C₆)-alkyl, CF₃, COO(C₁-C₆)-alkyl or COOH,

R3 is H or phenyl;

X is OH, O-(C_1 - C_6)-alkyl, NH₂, NH(C_1 - C_6)-alkyl or N((C_1 - C_6)-alkyl)₂;

A is N;

B, D, E are each CH;

m is 2;

[[and]] or a pharmaceutically acceptable salt[[s]] thereof.

5 (original). A pharmaceutical composition comprising one or more compounds of Claim 1 and a pharmaceutically acceptable carrier.

6-14 (canceled).